Back to Search
Start Over
BTKand PLCG2remain unmutated in one third of patients with CLL relapsing on ibrutinib
- Source :
- Blood Advances; 20230101, Issue: Preprints
- Publication Year :
- 2023
-
Abstract
- •One third of patients with CLL relapsing on ibrutinib do not carry BTK/PLCG2mutations, even with a 0.1% sensitivity.•Additional mechanisms, such as del(8p), EGR2and NF-κB pathway mutations, may be cooperating in determining progression on ibrutinib.
Details
- Language :
- English
- ISSN :
- 24739529 and 24739537
- Issue :
- Preprints
- Database :
- Supplemental Index
- Journal :
- Blood Advances
- Publication Type :
- Periodical
- Accession number :
- ejs62116641
- Full Text :
- https://doi.org/10.1182/bloodadvances.2022008821